Pacific Heights Asset Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-1,625
Closed -$432K – 79
2022
Q3
$432K Hold
1,625
– – 0.05% 80
2022
Q2
$721K Hold
1,625
– – 0.07% 83
2022
Q1
$2.01M Hold
1,625
– – 0.17% 81
2021
Q4
$4.1M Buy
1,625
+250
+18% +$1.53M 0.35% 73
2021
Q3
$25.2M Hold
1,375
– – 2.39% 6
2021
Q2
$14.6M Hold
1,375
– – 1.33% 19
2021
Q1
$9.91M Buy
1,375
+250
+22% +$1.8M 0.91% 36
2020
Q4
$6.25M Hold
1,125
– – 0.62% 52
2020
Q3
$11.3M Buy
1,125
+310
+38% +$2.82M 1.46% 23
2020
Q2
$7.55M Buy
815
+240
+42% +$2.2M 1.13% 26
2020
Q1
$5.73M Buy
+575
New +$5.68M 0.96% 36

Other funds holding IRLA

Pacific Heights Asset Management's IRLA Position: Q4 2022 in Review

Pacific Heights Asset Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2022, closing a stake of 1,625 shares — an estimated $432K sold.

Pacific Heights Asset Management first reported a position in IRLA in Q1 2020 and held it in 11 quarters. The position peaked at $25.2M in Q3 2021. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

  • Pacific Heights Asset Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Pacific Heights Asset Management sold 1,625 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $432K.
  • Pacific Heights Asset Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Pacific Heights Asset Management's IRulya Therapeutics Inc. Common Stock position peaked at $25.2M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on Pacific Heights Asset Management's 13F filing for Q4 2022, filed 10 Feb 2023.